Themis Medicare has launched a novel Opioid Injectable Analgesic Remifentanil under its brand name Remithem in the Indian market for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care.
Remifentanil was first approved in USA in 1996 and has wide clinical usage & acceptance around the world in major markets including USA, Europe, Japan and other countries and is also well published. The company has done pioneering work by conducting phase III trials at 13 centers in India before getting Remifentanil approved by the regulators. Remithem Remifentanil is considered to be a Dial In Opioid Analgesic as it has a quick onset of action, while it also has a very short context sensitive half-life enabling in addition a quick offset of action, while reducing the overall time in the OT and Post operative care room.
Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: